Status:
COMPLETED
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
Lead Sponsor:
University of Alberta
Conditions:
Cytomegalovirus Infection
Eligibility:
All Genders
18+ years
Brief Summary
Cytomegalovirus (CMV) is a common cause of illness in patients who have undergone a transplant. Serious infections due to CMV can affect many parts of the body including the lungs, the gut, and the li...
Detailed Description
CMV is the most common viral infection after solid organ transplantation (SOT) and is associated with significant morbidity1. Without prophylaxis, most CMV disease occurs in the first 3 months post-tr...
Eligibility Criteria
Inclusion
- Male or female patients who fulfill the following criteria are eligible for inclusion.
- CMV D+/R- liver, kidney, heart, pancreas, lungor combined transplant recipients
- All eligible patients must be scheduled to receive 3 months of either valganciclovir, oral ganciclovir, or intravenous ganciclovir prophylaxis.
- Able to give written informed consent
- Are willing and able to comply with the protocol
- Age \>=18 years
Exclusion
- \- Patient unwilling or unable to give informed consent
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
131 Patients enrolled
Trial Details
Trial ID
NCT00817908
Start Date
May 1 2008
End Date
April 1 2012
Last Update
April 23 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G-2E1